Chongqing Zhifei Biological Products Co., Ltd. (SHE:300122)
China · Delayed Price · Currency is CNY 15.47
+0.09 (0.59%)
May 8, 2026, 3:13 PM CST
SHE:300122 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 8,665 | 8,868 | 25,824 | 52,914 | 38,260 | 30,629 |
Other Revenue | 90.42 | 90.42 | 225.35 | 4.08 | 3.85 | 23.46 |
| 8,755 | 8,958 | 26,049 | 52,918 | 38,264 | 30,652 | |
Revenue Growth (YoY) | -48.52% | -65.61% | -50.77% | 38.30% | 24.83% | 101.79% |
Cost of Revenue | 21,797 | 21,874 | 18,966 | 38,986 | 25,518 | 15,728 |
Gross Profit | -13,042 | -12,916 | 7,083 | 13,932 | 12,746 | 14,925 |
Selling, General & Admin | 2,648 | 2,800 | 3,061 | 3,166 | 2,595 | 2,121 |
Research & Development | 916.62 | 932.3 | 1,021 | 968.47 | 854.16 | 552.63 |
Other Operating Expenses | 81.43 | 68.39 | 138.91 | 238.75 | 177.02 | 135.23 |
Operating Expenses | 4,212 | 4,265 | 4,828 | 4,725 | 4,047 | 3,000 |
Operating Income | -17,254 | -17,181 | 2,256 | 9,206 | 8,698 | 11,924 |
Interest Expense | -343.28 | -331.04 | -161.32 | -81 | -53.3 | -56.14 |
Interest & Investment Income | 20.92 | 24.67 | 66.69 | 67.94 | 46.09 | 61.47 |
Currency Exchange Gain (Loss) | 10.99 | 10.99 | 1.68 | 2.28 | 15.4 | -10.1 |
Other Non Operating Income (Expenses) | -51.11 | -51.43 | -37.52 | -36.56 | -22.64 | -17.23 |
EBT Excluding Unusual Items | -17,617 | -17,528 | 2,125 | 9,159 | 8,684 | 11,902 |
Gain (Loss) on Sale of Investments | -14.67 | -14.22 | 0.24 | - | - | -5.63 |
Gain (Loss) on Sale of Assets | -0.47 | 5.88 | 0.05 | 41.37 | 0.01 | 0.04 |
Asset Writedown | 7.68 | -0.38 | -0.36 | -0.13 | -0.09 | -1.68 |
Other Unusual Items | 50.13 | 44 | 37.34 | 142.34 | 34.31 | 35.83 |
Pretax Income | -17,574 | -17,493 | 2,163 | 9,342 | 8,718 | 11,931 |
Income Tax Expense | -2,766 | -2,747 | 222.15 | 1,272 | 1,179 | 1,723 |
Earnings From Continuing Operations | -14,808 | -14,745 | 1,940 | 8,070 | 7,539 | 10,209 |
Minority Interest in Earnings | 23.87 | 22.11 | 32 | - | - | - |
Net Income | -14,785 | -14,723 | 1,972 | 8,070 | 7,539 | 10,209 |
Net Income to Common | -14,785 | -14,723 | 1,972 | 8,070 | 7,539 | 10,209 |
Net Income Growth | - | - | -75.56% | 7.04% | -26.15% | 209.23% |
Shares Outstanding (Basic) | 2,394 | 2,394 | 2,395 | 2,400 | 2,400 | 2,400 |
Shares Outstanding (Diluted) | 2,394 | 2,394 | 2,395 | 2,400 | 2,400 | 2,400 |
Shares Change (YoY) | -0.05% | -0.06% | -0.20% | - | - | -0.00% |
EPS (Basic) | -6.18 | -6.15 | 0.82 | 3.36 | 3.14 | 4.25 |
EPS (Diluted) | -6.18 | -6.15 | 0.82 | 3.36 | 3.14 | 4.25 |
EPS Growth | - | - | -75.51% | 7.04% | -26.15% | 209.23% |
Free Cash Flow | 4,600 | 4,548 | -5,425 | 7,862 | 535.93 | 6,575 |
Free Cash Flow Per Share | 1.92 | 1.90 | -2.27 | 3.28 | 0.22 | 2.74 |
Dividend Per Share | - | - | 0.200 | 0.800 | 0.333 | 0.400 |
Dividend Growth | - | - | -75.00% | 140.02% | -16.68% | 20.01% |
Gross Margin | -148.97% | -144.17% | 27.19% | 26.33% | 33.31% | 48.69% |
Operating Margin | -197.08% | -191.79% | 8.66% | 17.40% | 22.73% | 38.90% |
Profit Margin | -168.87% | -164.35% | 7.57% | 15.25% | 19.70% | 33.30% |
Free Cash Flow Margin | 52.54% | 50.77% | -20.83% | 14.86% | 1.40% | 21.45% |
EBITDA | -16,726 | -16,682 | 2,636 | 9,518 | 9,003 | 12,297 |
EBITDA Margin | -191.05% | -186.22% | 10.12% | 17.99% | 23.53% | 40.12% |
D&A For EBITDA | 528.24 | 498.71 | 380.63 | 311.85 | 304.88 | 372.24 |
EBIT | -17,254 | -17,181 | 2,256 | 9,206 | 8,698 | 11,924 |
EBIT Margin | -197.08% | -191.79% | 8.66% | 17.40% | 22.73% | 38.90% |
Effective Tax Rate | - | - | 10.27% | 13.62% | 13.52% | 14.44% |
Revenue as Reported | 8,755 | 8,958 | 26,049 | 52,918 | 38,264 | 30,652 |
Advertising Expenses | - | 285.68 | 395.28 | 475.81 | 395.05 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.